Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

25,565 signal articles · 39 in last 24h · 122,512 total before filter · latest 54m ago
39last 24h
1244last 7d
205● bullish (7d)
149● bearish (7d)
205publishers
AllMacro210Earnings418M&A98Regulatory24Product8Analyst10
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Eli Lilly (LLY) Stock Looks Below Fair Value On Cash Flow
Simply Wall St.20d agoneutral
Eli Lilly (LLY) Stock Looks Below Fair Value On Cash Flow

Eli Lilly stock has delivered very strong gains over the past five years, yet the latest valuation checks send mixed signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a sizeable gap below the current price while the broader scorecard still leans expensive. Eli Lilly has returned about 357.2% over five years, which puts extra focus on whether the current price already reflects investors' optimism. The FDA's Breakthrough Therapy designation for olomorasib can...

Caterpillar (CAT) Is Teaming Up With WM To Test Autonomous Landfill Compactors
Simply Wall St.20d agoneutral
Caterpillar (CAT) Is Teaming Up With WM To Test Autonomous Landfill Compactors

WM and Caterpillar have agreed to collaborate on developing and testing autonomous landfill compactors for waste management operations. The partnership focuses on using autonomous heavy equipment to support safety and operational efficiency at landfill sites. The work centers on Caterpillar landfill compactors that can operate with reduced on site human intervention under controlled conditions. Caterpillar, traded as NYSE:CAT, is moving further into autonomous heavy equipment through this...

Schneider Electric (ENXTPA:SU) Posts Strong Half Year Earnings, Is It Still Undervalued?
Simply Wall St.20d agoneutral
Schneider Electric (ENXTPA:SU) Posts Strong Half Year Earnings, Is It Still Undervalued?

Schneider Electric (ENXTPA:SU) is back in focus after reporting half year 2026 earnings, with sales of €21,226m and net income of €2,488m, alongside fresh AI data center and safety research updates. See our latest analysis for Schneider Electric. The half year 2026 earnings release, together with Schneider Electric’s AI data center work with AMD and the potential Shelly Group acquisition, has arrived alongside firm price momentum. The 1-day share price return is 1.76% and the year to date...

Do Netflix’s APAC Brand Deals and Board Changes Hint at a Deeper Shift in Strategy (NFLX)?
Simply Wall St.20d agoneutral
Do Netflix’s APAC Brand Deals and Board Changes Hint at a Deeper Shift in Strategy (NFLX)?

In late July 2026, Netflix announced that Anne Sweeney resigned from its Board of Directors and appointed Kumar Kanagasabapathy as Director of Brand Partnerships for Asia Pacific, where he will lead regional brand tie-ups. These leadership moves highlight Netflix’s focus on strengthening governance while deepening its advertising and brand partnership capabilities across high-growth international markets. Next, we’ll examine how Kanagasabapathy’s appointment to lead APAC brand partnerships...

Palantir (PLTR) Is Turning Forward Deployed Engineering Into An Enterprise AI Playbook
Simply Wall St.20d agoneutral
Palantir (PLTR) Is Turning Forward Deployed Engineering Into An Enterprise AI Playbook

Palantir Technologies is drawing attention for its forward deployed engineering model, which is being used to handle rising complexity in enterprise AI integration. Industry observers report that more companies are building FDE-style programs that resemble Palantir’s approach to AI deployment. This shift highlights how Palantir’s methods are influencing wider enterprise AI adoption beyond its established government work. Palantir Technologies, ticker NasdaqGS:PLTR, is increasingly discussed...

Medicus Pharma CMO to lead  Antev's Teverelix clinical programme
Proactive20d agoneutral
Medicus Pharma CMO to lead Antev's Teverelix clinical programme

Medicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidiary Antev Limited, consolidating leadership of the Teverelix clinical programme ahead of regulatory, late-stage development and partnering work. Dr Faisal Mehmud will become Antev’s chief...